Cellectis SA (CLLS)
2.14
-0.11
(-4.89%)
USD |
NASDAQ |
Jun 17, 13:47
Cellectis Research and Development Expense (Quarterly): 22.32M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 22.32M |
December 31, 2023 | 25.53M |
September 30, 2023 | 18.89M |
June 30, 2023 | 22.14M |
March 31, 2023 | 21.42M |
December 31, 2022 | 21.43M |
September 30, 2022 | 23.84M |
June 30, 2022 | 25.63M |
March 31, 2022 | 26.60M |
December 31, 2021 | 21.18M |
September 30, 2021 | 34.32M |
June 30, 2021 | 31.15M |
March 31, 2021 | 31.00M |
December 31, 2020 | 13.45M |
September 30, 2020 | 20.10M |
June 30, 2020 | 22.86M |
March 31, 2020 | 20.72M |
December 31, 2019 | 30.44M |
September 30, 2019 | 21.60M |
Date | Value |
---|---|
June 30, 2019 | 25.42M |
March 31, 2019 | 14.51M |
December 31, 2018 | 21.40M |
September 30, 2018 | 18.69M |
June 30, 2018 | 18.04M |
March 31, 2018 | 18.40M |
December 31, 2017 | 20.70M |
September 30, 2017 | 20.29M |
June 30, 2017 | 18.61M |
March 31, 2017 | 19.58M |
December 31, 2016 | 20.19M |
September 30, 2016 | 15.43M |
June 30, 2016 | 21.72M |
March 31, 2016 | 21.39M |
December 31, 2015 | 17.22M |
September 30, 2015 | 18.18M |
June 30, 2015 | 14.34M |
March 31, 2015 | 8.053M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.45M
Minimum
Dec 2020
34.32M
Maximum
Sep 2021
24.00M
Average
22.59M
Median
Research and Development Expense (Quarterly) Benchmarks
Edap TMS SA | 2.247M |
DBV Technologies SA | 21.40M |
Genfit SA | -- |
Biophytis SA | -- |
Adaptimmune Therapeutics PLC | 35.21M |